アルツハイマーおよび関連する神経変性障害の処置のためのタウ凝集阻害剤としてのナフトキノン誘導体 - THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

Title:

アルツハイマーおよび関連する神経変性障害の処置のためのタウ凝集阻害剤としてのナフトキノン誘導体

Document Type and Number:

Japanese Patent JP2004534854

Kind Code:

A

Abstract:

Provided are napthoquinone-type compounds which can be used to modulate the aggregation of protein (e.g. tau) associated with neurodegenerative disease (e.g. Alzheimer's disease). Structure-function characteristics for oxidised and reduced napthoquinone-type compounds, such as menadione-related compounds, are disclosed. The invention further provides methods of treatment or prophylaxis of neurodegenerative diseases and/or clinical dementias based on the compounds.

More Like This:

JP2008037800	BENZOAZEPINE COMPOUND
WO/2023/104171	CHIMERIC ANTIGEN RECEPTOR T CELL SECRETING BISPECIFIC ANTIBODIES, PREPARATION METHOD THEREFOR AND USE THEREOF
JPWO2007094137	Methods for inducing cytotoxic T cells, inducers for cytotoxic T cells, and pharmaceutical compositions and vaccines using them.

Inventors:

Vischic, Claude Michelle
David Horsley
Rickard, Janet Elizabeth
Charles Robert, Harrington

Application Number:

JP2003513541A

Publication Date:

November 18, 2004

Filing Date:

July 16, 2002

Export Citation:

Click for automatic bibliography generation Help

Assignee:

THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

International Classes:

A61P1/16; A61K31/122; A61K31/192; A61K31/222; A61K31/255; A61P3/10; A61P7/02; A61P9/00; A61P25/00; A61P25/14; A61P25/16; A61P25/28; A61P29/00; A61P31/00; A61P35/00; A61P43/00; C07C50/10; C07C50/14; C07C50/24; C07C50/32; C07C50/38; C07C65/11; C07C69/16; C07C255/52; C07C305/22; C07C309/25; (IPC1-7): A61K31/122; A61K31/192; A61K31/222; A61K31/255; A61P1/16; A61P3/10; A61P7/02; A61P9/00; A61P25/00; A61P25/14; A61P25/16; A61P25/28; A61P29/00; A61P31/00; A61P35/00; A61P43/00; C07C50/10; C07C50/14; C07C50/24; C07C50/32; C07C50/38; C07C65/11; C07C69/16; C07C255/52; C07C305/22; C07C309/25

Domestic Patent References:

JPH11335244A	1999-12-07
JPH11502925A	1999-03-09
JPH06505005A	1994-06-09
JPS61143334A	1986-07-01
JPH11335244A	1999-12-07
JPH11502925A	1999-03-09
JPH06505005A	1994-06-09
JPS61143334A	1986-07-01

Foreign References:

DE19504003A1	1996-08-14
WO1997003940A1	1997-02-06
US4560511A	1985-12-24
DE19504003A1	1996-08-14
WO1997003940A1	1997-02-06
US4560511A	1985-12-24

Other References:

JPN7009003142; ＣＨＥＭＩＣＡＬ　ＲＥＳＥＡＲＣＨ　ＩＮ　ＴＯＸＩＣＯＬＯＧＹ１１（６）, 1998, Ｐ．６０８-６１３
JPN6009032507; ＨＥＴＥＲＯＣＹＣＬＩＣ　ＣＯＭＭＵＮＩＣＡＴＩＯＮＳ５（４）, 1999, Ｐ．３４３-３４８
JPN6009032508; ＰＨＡＲＭＡＣＹ　ＡＮＤ　ＰＨＡＲＭＡＣＯＬＯＧＹ　ＣＯＭＭＵＮＩＣＡＴＩＯＮＳ５（４）, 1999, Ｐ．２８１-２８５
JPN7009003143; ＩＮＤＩＡＮ　ＪＯＵＲＮＡＬ　ＯＦ　ＰＨＡＲＭＡＣＯＬＯＧＹ３１（３）, 1999, Ｐ．２２２-２２４
JPN7009003142; ＣＨＥＭＩＣＡＬ　ＲＥＳＥＡＲＣＨ　ＩＮ　ＴＯＸＩＣＯＬＯＧＹ１１（６）, 1998, Ｐ．６０８-６１３
JPN6009032507; ＨＥＴＥＲＯＣＹＣＬＩＣ　ＣＯＭＭＵＮＩＣＡＴＩＯＮＳ５（４）, 1999, Ｐ．３４３-３４８
JPN6009032508; ＰＨＡＲＭＡＣＹ　ＡＮＤ　ＰＨＡＲＭＡＣＯＬＯＧＹ　ＣＯＭＭＵＮＩＣＡＴＩＯＮＳ５（４）, 1999, Ｐ．２８１-２８５
JPN7009003143; ＩＮＤＩＡＮ　ＪＯＵＲＮＡＬ　ＯＦ　ＰＨＡＲＭＡＣＯＬＯＧＹ３１（３）, 1999, Ｐ．２２２-２２４

Attorney, Agent or Firm:

Hajime Tsukuni
Fumio Shinoda

Previous Patent: 無水ユビキノン濃縮物

Next Patent: 第ＶＩＩ因子ポリペプチドおよび第ＸＩ因子ポリペプチドを含んでなる医�...